Table 2.

Independent prognostic factors for overall survival (OS).

Characteristics		Univariate analysis			Multivariate analysis
		HR	95%CI	P	HR	95%	P
Age	≤60 years	Reference		0.827			NI
	>60 years	0.952	0.610–1.484
Gender	Male	Reference		0.032	Reference
	Female	1.632	1.042–2.556		1.793	0.984–2.965	0.063
WBC (*109)	≤10	Reference		0.376			NI
	>10	1.461	0.631–3.384
HGB (g/L)	≤120	Reference		0.701			NI
	>120	1.093	0.694–1.722
PLT (*109)	≤100	Reference		0.839			NI
	>100	0.946	0.552–1.619
ALT (U/L)	≤40	Reference		0.377			NI
	>40	0.815	0.518–1.283
AST (U/L)	≤40	Reference		0.062			NI
	>40	0.638	0.398–1.023
ALP (U/L)	≤100	Reference		0.376			NI
	>100	0.818	0.524–1.276
GGT (U/L)	≤45	Reference					NI
	>45	0.783	0.502–1.223	0.282
ALB (g/L)	≤40	Reference					NI
	>40	0.821	0.494–1.367	0.449
TBIL (umol/L)	≤20.5	Reference					NI
	>20.5	0.776	0.492–1.224	0.276
IBIL (umol/L)	≤15	Reference					NI
	>15	0.962	0.555–1.668	0.890
CRP (ng/L)	≤3	Reference					NI
	>3	0.956	0.612–1.493	0.842
CEA (ng/mL)	≤5	Reference		0.552			NI
	>5	1.144	0.734–1.785
CA19-9 (U/ml)	≤35	Reference		0.110			NI
	>35	1.570	0.903–2.728
Tumor size (cm)	≤2	Reference			Reference
	2~4	1.274	0.681–2.382	0.449	1.418	0.714–2.817	0.318
	>4	2.663	1.417–5.008	0.002	2.075	0.980–4.395	0.056
Tumor site	Head	Reference					NI
	Body/Tail	1.150	0.821–1.609	0.417
Treatment	Chemotherapy	Reference			Reference
	Conversional surgery	0.269	0.141–0.513	<0.001	0.274	0.133–0.564	<0.001
	Chemotherapy + IRE	0.266	0.146–0.485	<0.001	0.349	0.177–0.686	0.002
Chemotherapy type	S-1	Reference					NI
	AG	0.592	0.256–1.369	0.220
	FOLFIRINOX	1.248	0.717–2.172	0.433
Imaging LN metastasis	Absence	Reference			Reference
	Present	1.785	1.123–2.838	0.014	1.045	0.598–1.826	0.878
HBsAg	No	Reference					NI
	Yes	1.311	0.630–2.730	0.469

OS, overall survival; HR, hazard ratio; CI, confidence interval; NI, not include, other abbreviations as in Table 1 .